I've said this a few times now, but the pace at which the science is unfurling in the COVID-19 vaccine and therapeutics development is absolutely unprecedented. When I wrote that op-ed, the CanSino collaboration agreement didn't exist yet.
I think that point is emphasized by what Mr. Fisher mentioned. The clinical trials work is going to be done by researchers at Dalhousie University, who have expertise in doing these kinds of clinical trials. There is expertise in doing at least some kinds of phase I through phase III clinical trials that exists in universities and other research institutes and in other places. There are models of innovation that do not have to rely solely on the sale of early-stage promising drug and vaccine candidates to the private sector. There are different ways of doing this.